# Daily Iteration Report — 2026-04-24

## Summary
Scheduled research-agent run on Friday 2026-04-24. Worked 3 meaningful queue items, ran credibility sweep, rebuilt the full pipeline (41/41 [OK]), and committed locally. Push deferred (no HTTPS credentials in non-interactive shell).

## Work completed

### 1. Paper vetting batch (12 papers → VETTED)
All 12 PMIDs verified against `paper_library/index.json` — titles, journals, years match. Abstracts scanned for red flags; none found.

| PMID | Journal | Year | Note |
|---|---|---|---|
| 9828138 | Genomics | 1998 | IA-2/PTPRN genomic structure |
| 9867128 | Autoimmunity | 1998 | Dapsone in NOD mouse |
| 29590046 | Science | 2018 | Shen et al. fiber → SCFA-producing bacteria → HbA1c RCT |
| 29617641 | Cell Metabolism | 2018 | Drucker GLP-1 mechanisms review |
| 29619531 | Diabetologia | 2018 | Action LADA N-terminally truncated GAD65 |
| 29623672 | Am J Cardiovasc Drugs | 2018 | NAC in diabetic cardiomyopathy SR |
| 29710129 | JAMA Oncol | 2018 | CAR-T administration cost letter (brief by design) |
| 29754952 | Cell Metabolism | 2018 | Sutton eTRF proof-of-concept trial |
| 29885104 | Diabetes Metab J | 2018 | Glycated albumin vs HbA1c for uNAG tubulopathy |
| 29909913 | Best Pract Res Clin Haematol | 2018 | GMP CAR-T manufacturing review |
| 29988125 | Nat Med | 2018 | Ovalle verapamil T1D Phase 2 RCT (landmark) |
| 30041834 | Trends Endocrinol Metab | 2018 | LADA global perspective review |

Running totals: **152 VETTED / 9 FLAGGED / 106 UNVETTED** (of 267).

### 2. Research path VALIDATED: `SGLT2i_NLRP3_DKD`
Mechanism: SGLT2i (dapagliflozin, empagliflozin) → reduced NLRP3 inflammasome activation in renal tubular cells via (a) β-hydroxybutyrate-induced NLRP3 inhibition, (b) TCA-cycle immunometabolite itaconate accumulation, and (c) reduced RIP1-RIP3-MLKL necroinflammation → decreased IL-1β/IL-18/NLRP3 expression → attenuated renal fibrosis.

Confidence: **HIGH preclinical / MEDIUM clinical**. Supporting PMIDs:
- 34918381 (Ke et al. FASEB J 2022 — dapagliflozin/itaconate)
- 35069210 (Front Pharmacol 2022 — RIP1-RIP3-MLKL)
- 39412512 (Braz J Nephrol 2024 narrative review)
- 37242177 (Nutrients 2023 review)

Explicit caveats recorded: all mechanistic evidence is preclinical; **no human RCT has directly measured NLRP3 as a mediator** of SGLT2i renal benefit. The downstream clinical benefit (CREDENCE, DAPA-CKD, EMPA-KIDNEY; Lancet 2022 meta-analysis) is well-established independently — NLRP3 is the most parsimonious mechanistic explanation but remains unproven in humans.

### 3. Gap 7 audit: SILVER retained
GWAS/Polygenic × Closed Loop / Artificial Pancreas. Verdict: **gap remains real**.

Searched 2025-2026 literature. Found active PRS T1D publications (Diabetologia 2023, Nat Rev Endocrinol 2025, medRxiv 2025 trans-ancestry T1D PRS) and robust closed-loop literature (Control-IQ NEJM, CamAPS-FX, MiniMed 780G). **No study intersects the two** — no work has asked whether PRS/GRS predicts glycemic response to automated insulin delivery. Cross-domain blind spot confirmed.

## Credibility sweep
Scanned all `.py` scripts in Analysis/Scripts for:
- PMIDs > 42,000,000 (fabricated threshold): **0 hits**
- "zero SAEs" / "zero rejection": **0 hits**
- "curative" / "achieves cure" in preclinical context: **0 real hits** (2 self-referential hits inside `verify_before_deploy.py`'s own regex patterns)

Clean.

## Pipeline rebuild
`python Analysis/Scripts/run_quality_improvements.py` — **41 / 41 steps [OK]**.

## Git
Committed locally as `db60ea2`. Push deferred — HTTPS credentials not available in the non-interactive scheduled-task shell. Next user-initiated session can push.

## Reprioritized work queue (next run)
1. vet_papers_batch (106 remaining; next PMIDs 30303773, 30415610, 30586620, 30657336, 30899369, 30949058, 31036962, 31157579, 31173679, 31175156)
2. search_pubmed: Abata ABA-201 CAR-Treg T1D readout
2. search_pubmed: DIAMYD DIAGNODE Extension
2. validate_path: BHB → NLRP3 (new path surfaced by today's SGLT2i work)
3. audit_gap: Gap 14 (monthly BRONZE)
3. search_pubmed: LADA personalized-nutrition RCT (monthly)
3. check_combination: dapagliflozin + colchicine
4. search_pubmed: teplizumab PROTECT extension
4. audit_gap: Gap 1 (quarterly SILVER)
4. audit_gap: Gap 9 (exploratory GKA × LADA)
